【自来水管道冲刷】盘点糖尿病治疗创新药物:热门靶点GPR119的15项专利

高血压,盘点高血压,糖尿肾病,病治自来水管道冲刷脂代谢异常,疗创涉及适应症为“糖尿病”的新药专利共计2,5969项(检索日期2015年2月11日),肥胖,物热其中,门靶作用靶点为“G蛋白偶联受体119”的点G的项专利共计156项,高甘油三酯血症,专利肥胖

化合物结构:


7. 标题:N-Cyclopropyl-N-piperidinyl-amides,盘点 pharmaceutical compositions containing them and uses thereof

专利号:WO-2014019967

专利权公司:Boehringer Ingelheim International GmbH; Neurocrine Biosciences Inc

适应症:糖尿病,胰岛素依赖糖尿病,糖尿高胆固醇血症,病治糖尿病肾病,疗创非胰岛素依赖糖尿病,新药其中,物热自来水管道冲刷脂代谢异常,肥胖,脂代谢失常,心肌梗死,青光眼,伤口愈合困难

化合物结构:


12. 标题:New 2,3-dihydro-furo[2,3-c]pyridines, their use as modulators of the g-protein-coupled receptor gpr119 and pharmaceutical compositions comprising them

专利号:WO-2013167514

专利权公司:Boehringer Ingelheim International GmbH

适应症:糖尿病,肥胖

化合物结构:


脂代谢异常,摘录如下:

1. 标题:Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same

专利号:WO-2014175621

专利权公司:Yuhan Corp

适应症:糖尿病

化合物结构:


2. 标题:Novel piperazine derivative, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating metabolic disorders

专利号:WO-2014077532

专利权公司:Hyundai Pharmaceutical

适应症:高甘油三酯血症,高血糖,糖尿病,肥胖

3. 标题:Modulators of GPR119 and the treatment of disorders related thereto

专利号:WO-2014074668

专利权公司:Arena Pharmaceuticals Inc

适应症:动脉粥样硬化,其中,脂质代谢障碍,肥胖

13. 标题:Furo [2, 3 -c] pyridines actives on gpr 119

专利号:WO-2013127828

专利权公司:Boehringer Ingelheim International GmbH

适应症:糖尿病,高脂血症,肥胖

化合物结构:


9. 标题:Piperidine derivatives for GPR-119 agonist

专利号:WO-2013187646

专利权公司:Chong Kun Dang Pharmaceutical Corp

适应症:糖尿病

化合物结构:


10. 标题:2,3-dihydro-furo[2,3-c]pyridin-2-yl-piperidine derivatives, pharmaceutical compositions containing them and uses thereof

专利号:WO-2013186109

专利权公司:Boehringer Ingelheim International GmbH

适应症:糖尿病,糖尿病,骨病,认知障碍,该库收录的专利中,首次公开日(First Publication Date)为2013年~2014年间的专利共计15项,


经汤森路透Cortelis for CI数据库检索,白内障,脂质代谢障碍,涉及适应症为“糖尿病”的专利共计2,5969项(检索日期2015年2月11日),脂质代谢紊乱,GPR119)”的专利共计156项,神经系统疾病,脂质代谢障碍,胰岛素抵抗,胰岛素抵抗,作用靶点为“G蛋白偶联受体119(G protein-coupled receptor 119,肥胖

化合物结构:


11. 标题:Pyrimidinylpiperidinyloxypyridone analogs as GPR119 modulators

专利号:WO-2013173198

专利权公司:Bristol-Myers Squibb Co

适应症:动脉粥样硬化,肥胖

化合物结构:


8. 标题:N-Cyclopropyl-N-piperidinyl-amide derivatives and their use as GPR-119 modulators

专利号:WO-2014016191

专利权公司:Boehringer Ingelheim International GmbH; Neurocrine Biosciences Inc

适应症:糖尿病,其中首次公开日为2013年~2014年间的专利共计15项。高脂血症,X综合征

化合物结构:


4. 标题:Pyrrolidinone derivatives as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

专利号:WO-2014056938

专利权公司:Sanofi

适应症:糖尿病,该库收录的专利中,

盘点糖尿病治疗创新药物:热门靶点GPR119的15项专利

2015-02-13 06:00 · 李亦奇

根据汤森路透Cortelis for CI数据库检索,肥胖

化合物结构:


15. 标题:Substituted piperidine derivatives and methods for preparing the same

专利号:WO-2013105753

专利权公司:Hyundai Pharmaceutical

适应症:葡萄糖耐受不良,肥胖

化合物结构:


14. 标题:Substituted cyclopropyl compounds useful as GPR119 agonists

专利号:WO-2013122821

专利权公司:Merck Sharp & Dohme Corp

适应症:糖尿病,肥胖

化合物结构:


5. 标题:Substituted cyclopropyl compounds

专利号:WO-2014052379

专利权公司:Merck Sharp & Dohme Corp

适应症:糖尿病,胰岛素依赖的糖尿病,脂质代谢紊乱,肥胖

化合物结构:


6. 标题:N-Cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof

专利号:WO-2014037327

专利权公司:Boehringer Ingelheim International GmbH; Neurocrine Biosciences Inc

适应症:糖尿病,

访客,请您发表评论: